Clover Health Investments, Corp. (CLOV)
Automate Your Wheel Strategy on CLOV
With Tiblio's Option Bot, you can configure your own wheel strategy including CLOV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLOV
- Rev/Share 3.1596
- Book/Share 0.6763
- PB 3.8783
- Debt/Equity 0.0
- CurrentRatio 1.7972
- ROIC -0.1128
- MktCap 1344321596.0
- FreeCF/Share -0.0947
- PFCF -27.8905
- PE -30.9712
- Debt/Assets 0.0
- DivYield 0
- ROE -0.1264
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CLOV | Craig Hallum | -- | Buy | -- | $6 | Dec. 17, 2024 |
| Initiation | CLOV | UBS | -- | Neutral | -- | $4 | Oct. 7, 2024 |
News
Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Clover Health Investments (CLOV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Clover Health: Short-Term Pain Hides Its Long-Term Profitability Potential
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
While Clover Health's Q2 earnings showed continued member and revenue growth, it dropped 30% since then due to higher medical costs that impacted all MA plan providers. Clover Health still maintains industry-leading medical cost ratios despite the short-term cost headwinds, a testament to its tech-based business model. The implementation of negotiated drug prices in 2026, combined with the 5.06% MA payout increase by CMS and the 5% quality bonus, could help Clover offset the higher medical costs.
Read More
CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.
Read More
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.
Read More
Clover Health Appoints Joseph Oldakowski as Vice President of Finance and Controller
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function.
Read More
All You Need to Know About Clover Health Investments (CLOV) Rating Upgrade to Strong Buy
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.
Read More
Clover Health Investments, Corp. (CLOV) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Matt Hewitt - Craig-Hallum Capital Richard Close - Canaccord Genuity Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Read More
Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.05 per share a year ago.
Read More
Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.
Read More
Clover Health Investments, Corp. (CLOV) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Tolf Cormanon - Craig Hallam Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Read More
Clover Health Investments, Corp. (CLOV) Tops Q4 Earnings Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.12 per share a year ago.
Read More
About Clover Health Investments, Corp. (CLOV)
- IPO Date 2020-06-12
- Website https://www.cloverhealth.com
- Industry Medical - Healthcare Plans
- CEO Andrew Toy
- Employees 570